122 related articles for article (PubMed ID: 219695)
1. Hexamethylmelamine: an evaluation of its role in the treatment of ovarian cancer.
Wharton JT; Rutledge F; Smith JP; Herson J; Hodge MP
Am J Obstet Gynecol; 1979 Apr; 133(7):833-44. PubMed ID: 219695
[TBL] [Abstract][Full Text] [Related]
2. Hexamethylmelamine as a single second-line agent in ovarian cancer.
Manetta A; MacNeill C; Lyter JA; Scheffler B; Podczaski ES; Larson JE; Schein P
Gynecol Oncol; 1990 Jan; 36(1):93-6. PubMed ID: 2104819
[TBL] [Abstract][Full Text] [Related]
3. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.
Stehman FB; Ehrlich CE; Callangan MF
Gynecol Oncol; 1984 Feb; 17(2):189-95. PubMed ID: 6423460
[TBL] [Abstract][Full Text] [Related]
4. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma.
Johnson BL; Fisher RI; Bender RA; DeVita VT; Chabner BA; Young RC
Cancer; 1978 Nov; 42(5):2157-61. PubMed ID: 102417
[TBL] [Abstract][Full Text] [Related]
5. Hexamethylmelamine and pentamethylmelamine: an update.
Hahn DA
Drug Intell Clin Pharm; 1983 Jun; 17(6):418-24. PubMed ID: 6407810
[TBL] [Abstract][Full Text] [Related]
6. Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy.
Rosen GF; Lurain JR; Newton M
Gynecol Oncol; 1987 Jun; 27(2):173-9. PubMed ID: 3106174
[TBL] [Abstract][Full Text] [Related]
7. Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
Foster BJ; Clagett-Carr K; Marsoni S; Simon R; Leyland-Jones B
Cancer Treat Rep; 1986 Aug; 70(8):1003-14. PubMed ID: 3089597
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
Kardinal CG; Luce JK
Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
[TBL] [Abstract][Full Text] [Related]
9. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group.
Wiernik PH; Yeap B; Vogl SE; Kaplan BH; Comis RL; Falkson G; Davis TE; Fazzini E; Cheuvart B; Horton J
Cancer Invest; 1992; 10(1):1-9. PubMed ID: 1735009
[TBL] [Abstract][Full Text] [Related]
10. Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma.
Moore DH; Valea F; Crumpler LS; Fowler WC
Gynecol Oncol; 1993 Oct; 51(1):109-12. PubMed ID: 8244164
[TBL] [Abstract][Full Text] [Related]
11. Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine).
Manetta A; MacNeill C; Lyter JA; Scheffler B; Podczaski ES; Larson JE; Schein P
Cancer Treat Rev; 1991 Mar; 18 Suppl A():23-9. PubMed ID: 1904305
[TBL] [Abstract][Full Text] [Related]
12. Hexamethylmelamine. An evaluation of its role in the therapy of cancer.
Legha SS; Slavik M; Carter SK
Cancer; 1976 Jul; 38(1):27-35. PubMed ID: 820422
[TBL] [Abstract][Full Text] [Related]
13. The role of hexamethylmelamine in advanced ovarian carcinoma treatment.
Weiss RB
Gynecol Oncol; 1981 Oct; 12(2 Pt 1):141-9. PubMed ID: 6795094
[No Abstract] [Full Text] [Related]
14. Hexamethylmelamine chemotherapy for disseminated endometrial cancer.
Seski JC; Edwards CL; Copeland LJ; Gershenson DM
Obstet Gynecol; 1981 Sep; 58(3):361-3. PubMed ID: 6791063
[TBL] [Abstract][Full Text] [Related]
15. Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy.
Kwon YS; Nam JH; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT
J Korean Med Sci; 2009 Aug; 24(4):679-83. PubMed ID: 19654952
[TBL] [Abstract][Full Text] [Related]
16. Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer.
Moore DH; Fowler WC; Jones CP; Crumpler LS
Am J Obstet Gynecol; 1991 Sep; 165(3):573-6. PubMed ID: 1909840
[TBL] [Abstract][Full Text] [Related]
17. cis-Dichlorodiammineplatinum (II) and hexamethylmelamine in advanced ovarian carcinoma: a phase II study.
Lund B; Aabo K; Rørth M; Hansen HH
Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1089-92. PubMed ID: 6819145
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
Bonomi PD; Mladineo J; Morrin B; Wilbanks G; Slayton RE
Cancer Treat Rep; 1979 Jan; 63(1):137-8. PubMed ID: 105805
[No Abstract] [Full Text] [Related]
19. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.
Boven E; Nauta MM; Schlüper HM; Erkelens CA; Pinedo HM
Cancer Chemother Pharmacol; 1986; 18(2):124-8. PubMed ID: 3098444
[TBL] [Abstract][Full Text] [Related]
20. Contribution of prednisone to the effectiveness of hexamethylmelamine in multiple myeloma.
Oken MM; Lenhard RE; Tsiatis AA; Glick JH; Silverstein MN
Cancer Treat Rep; 1987 Sep; 71(9):807-11. PubMed ID: 3113729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
